LAUSR

2020. https://doi.org/10.3324/haematol.2020.247973 [Epub ahead of print]. 10. Plesner T, Krejcik J. Daratumumab for the treatment of multiple myeloma. Front Immunol. 2018;9:1228. 11. Lia G, Di Vito C, Cerrano M, Brunello L, Calcaterra F, Tapparo M, et al. Extracellular vesicles after allogeneic hematopoietic cell transplantation: emerging role in post-transplant complications. Front Immunol. 2020;11. https://doi.org/10.3389/fimmu.2020.00422. 12. Ghose J, Viola D, Terrazas C, Caserta E, Troadec E, Khalife J, et al. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology. 2018;7:e1486948. 13. Morandi F, Marimpietri D, Horenstein AL, Bolzoni M, Toscani D, Costa F, et al. Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD. Oncoimmunology. 2018;7:e1458809. 14. G€ okbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522–31. 15. Yang K, Xu J, Liu Q, Li J, Xi Y. Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia. Pathol Res Pract. 2019;215:265–71.